Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament lightMark HJ Wessels, Charlotte E. Teunissen, Bernard M.J. Uitdehaag et al.|Multiple Sclerosis Journal|2023Cited by 17
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)Alyssa A Toorop, Zoé L. E. van Kempen, Beatrijs Wokke et al.|Journal of Neurology Neurosurgery & Psychiatry|2023Cited by 17
Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosisZoë YGJ van Lierop, Joep Killestein, Martijn D. Steenwijk et al.|Multiple Sclerosis Journal|2022Cited by 11